We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Adc Therapeutics Sa
3 own
4 watching
Current Price
$2.5
$-0.05
(-1.96%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
192.03M
52-Week High
10.88
52-Week Low
1.85
Average Volume
0.1M
Dividend Yield
--
P/E Ratio
--
Market Capitalization192.03M52-Week High10.8852-Week Low1.85Average Volume0.1MDividend Yield--P/E Ratio--What does the Adc Therapeutics Sa do?
ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL in second-line transplant-ineligible patients; and Phase I clinical trial for treatment of relapsed or refractory non-hodgkin lymphoma (NHL). The company is also developing camidanlumab tesirine, an ADC that has completed Phase I clinical trial to treat relapsed or refractory NHL; in Phase II clinical trial in relapsed or refractory hodgkin lymphoma; and in Phase Ib clinical trial for selected advanced solid tumors. In addition, it develops ADCT-602, which is in Phase Ia clinical trial for treatment of acute lymphoblastic leukemia; ADCT-601 and ADCT-901 that are in Phase Ia clinical trial for treatment of various solid tumors; and preclinical product candidates, including ADCT-701 and ADCT-901 for the treatment of solid tumors. It has a collaboration and license agreement with Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.
Read More
News & Events about Adc Therapeutics Sa.
PR Newswire
2 months ago
PharmaVentures establishes an office in Seoul to enhance access for South Korean biotechs PharmaVentures establishes an office in Seoul to enhance access for South Korean biotechs PR Newswire LONDON, March 29, 2023 LONDON, March 29, 2023 /PRNewswire/ -- PharmaVentures announces its new office in...
Zolmax
2 months ago
Shares of ADC Therapeutics SA (NYSE:ADCT Get Rating) have earned a consensus rating of Moderate Buy from the six ratings firms that are presently covering the company, MarketBeat reports. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to ...
Ticker Report
3 months ago
ADC Therapeutics SA (NYSE:ADCT Get Rating) Analysts at Capital One Financial issued their FY2027 earnings per share (EPS) estimates for shares of ADC Therapeutics in a research report issued to clients and investors on Wednesday, March 1st. Capital One Financial analyst N. Quibria ...
Ticker Report
4 months ago
ADC Therapeutics (NYSE:ADCT Get Rating) had its price objective cut by analysts at Morgan Stanley from $7.00 to $5.00 in a research report issued on Tuesday, Benzinga reports. The firm presently has an equal weight rating on the stock. Morgan Stanleys price target points...
Frequently Asked Questions
Frequently Asked Questions
What is Adc Therapeutics Sa share price today?
Can Indians buy Adc Therapeutics Sa shares?
How can I buy Adc Therapeutics Sa shares from India?
Can Fractional shares of Adc Therapeutics Sa be purchased?
What are the documents required to start investing in Adc Therapeutics Sa stocks?
What is today’s traded volume of Adc Therapeutics Sa?
What is today’s market capitalisation of Adc Therapeutics Sa?
What is the 52-Week High and Low Range of Adc Therapeutics Sa?
What percentage is Adc Therapeutics Sa down from its 52-Week High?
What percentage is Adc Therapeutics Sa up from its 52-Week Low?
Current Price
$2.5
$-0.05
(-1.96%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.